Immunovant, Inc. (IMVT)
UndervaluedFundamental
23
Price
$28.41
Market Cap
$5.86B
Part 1 · What the company is worth
Overview
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated with artificial intelligence on September 18, 2026, shared with all users
argenx sells efgartigimod (Vyvgart), the first approved FcRn blocker, and competes with Immunovant's IMVT-1402 for the same autoimmune patients in myasthenia gravis, CIDP and other IgG-driven diseases.
Johnson & Johnson markets the FcRn blocker nipocalimab (Imaavy) in generalized myasthenia gravis and is expanding it into Sjögren's disease and other indications Immunovant is also targeting.
UCB's rozanolixizumab (Rystiggo) is an approved FcRn blocker for generalized myasthenia gravis, competing for the same neurologists and the same patients Immunovant's lead programme addresses.
Viridian sells veligrotug (Lumvoa) for thyroid eye disease and is developing its own FcRn inhibitors, putting it head-to-head with Immunovant in the thyroid autoimmune indications built around Graves' disease.
Biohaven is developing BHV-1300, an IgG-degrading therapy aimed at Graves' disease and other antibody-driven autoimmune conditions, the same indications Immunovant has chosen for IMVT-1402.
Balance Sheet & Liquidity
Revenue
0
Fiscal year ended 3/31/2026
Net Income
$-506M
Fiscal year ended 3/31/2026
Free Cash Flow
$-407M
Total Equity
$853M
Total Liabilities
$104M
Current Ratio
7.27
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
No income data available
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$48.88
Current Price
$28.41
Margin of Safety
+41.9%
Fair Value Range
$46.43 - $51.32
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-59.3%
P/B Ratio
7.98
P/FCF
-
Gross Margin
-
ROIC
-
Profitability Radar
Value Creation (Economic Moat)
ROIC
-
WACC
9.6%
ROIC − WACC
-
Fundamental Analysis Criteria
Passed (4)
- Price CAGR 11.75%
- Debt/equity ratio
- Current ratio
- Low reliance on intangibles
Failed (9)
- EPS shows upward trend
- P/B ratio 7.98
- Positive free cash flow
- Return on tangible assets
- DCF valuation (Unknown)
- ROE -69.6%
- Earnings surprise, average -11.4%
- Share dilution 20.4%
- Piotroski F-Score 2/9
Unavailable (13)
- ROIC –
- Gross margin –
- P/FCF –
- Dividend payout –
- Operating margin –
- CapEx intensity
- Interest coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue growth 5Y
- PEG ratio (needs P/E > 0 and growth > 0)
- Earnings quality (operating cash flow / net income)
- Net margin trend (invalid data)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 46 |
| Dr. Eric Venker M.D., Pharm.D. | CEO & Director | 38 |
| Mr. Tiago M. Girao CPA | Chief Financial Officer | 46 |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer | 47 |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer | 62 |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary | 50 |
| Ms. Christine Blodgett | Senior Vice President of Human Resources | - |
| Ms. Becky Merlina | Senior VP & Global Head of Quality | - |
| Ms. Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming & Data Management | - |
| Ms. Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development | - |
Audit Risk
4
Board Risk
10
Compensation Risk
9
Shareholder Rights Risk
10
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-05-20
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-06
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-03
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much IMVT moves, measured on its daily prices.
More volatile than 53% of the tracked stocks (90-day volatility).
- Volatility 30d
- 40.0%
- Volatility 90d
- 37.5%
- Beta vs S&P 500 (1y)
- 1.32Correlation 0.29
- Max drawdown (12m)
- -40.5%
- ATR (14d, % of price)
- 4.54%
Earnings reactions
How IMVT moved around its past quarterly results.
Next earnings release
Nov 9, 2026 · In 16 days · Before the open
EPS estimate: -0.72Revenue estimate: $0
What usually happens
- Over the last 12 releases the stock moved a median of 5.2% the next day, up or down.
- Next-day moves: up 6, down 6 (out of 12).
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | During the session | -0.63 | -0.75 | -19.5% | -3.3% | +1.2% | +8.5% |
| May 20, 2026 | During the session | -0.61 | -0.73 | -19.1% | +15.8% | +35.3% | +27.1% |
| Feb 6, 2026 | During the session | -0.73 | -0.61 | +16.3% | +11.7% | +12.4% | +6.6% |
| Nov 10, 2025 | During the session | -0.73 | -0.73 | +0.2% | -2.5% | +0.1% | +1.7% |
| Aug 11, 2025 | During the session | n/a | n/a | n/a | +0.3% | -4.5% | -1.6% |
| May 29, 2025 | During the session | -0.73 | -0.64 | +12.4% | +4.6% | +5.6% | +8.8% |
| Feb 6, 2025 | During the session | n/a | n/a | n/a | +2.2% | -9.6% | -14.6% |
| Nov 7, 2024 | During the session | n/a | n/a | n/a | -0.5% | -4.7% | -8.0% |
| Aug 6, 2024 | After the close | n/a | n/a | n/a | +0.3% | -3.1% | +7.0% |
| May 29, 2024 | After the close | n/a | n/a | n/a | -6.3% | -10.7% | -13.4% |
| Feb 12, 2024 | During the session | n/a | n/a | n/a | -4.4% | +3.4% | +4.6% |
| Nov 9, 2023 | During the session | n/a | n/a | n/a | -2.2% | -6.2% | +2.5% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on IMVT and what the price did next.
- 3/15/2026PositiveA Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
- +1 day
- +1.4%
- +3 days
- -3.2%
- 3/11/2026PositiveImmunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for IMVT.
- 3/15/2026POSITIVEA Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
A healthcare hedge fund has significantly increased its stake in Immunovant Inc., acquiring an additional $24.5 million worth of stock. Immunovant is a clinical-stage biopharmaceutical company focused on developing antibody therapies for autoimmune diseases. Its lead candidate is currently undergoing Phase II trials. This substantial investment by a specialized healthcare fund suggests strong conviction in the company's pipeline and future prospects. For investors, this move could signal positive upcoming developments or a favorable risk-reward profile for Immunovant's stock.
- 3/11/2026POSITIVEImmunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Inc. (IMVT) experienced a significant surge, with its stock price climbing 30%. This upward momentum comes despite a notable insider trimming their stake by $3 million. The company, which focuses on antibody therapies for autoimmune diseases, has seen its lead candidate advance through clinical trials. This progress in its drug development pipeline is a key driver for investor optimism, suggesting potential future revenue streams and market expansion. The stock's performance indicates strong market confidence in Immunovant's therapeutic pipeline and its long-term growth prospects, outweighing the impact of the insider's partial divestment.